Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

Paris (France), October 13, 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the International Sepsis Forum held in Barcelona the results for its Phase IIb ASTONISH clinical trial in septic shock patients.

Read full article (PDF)